阿扎那韦

Description

Atazanavir · CAS 198904-31-3 · C38H52N6O7. UNII QZU4H47A3S. Solubility: 3.27e-03 g/L; LogP: 4.5.

Identification

CAS Registry Number	198904-31-3
PubChem CID	148192
Molecular formula	C38H52N6O7
IUPAC name	methyl N-[(2S)-1-[2-[(2S,3S)-2-hydroxy-3-[[(2S)-2-(methoxycarbonylamino)-3,3-dimethylbutanoyl]amino]-4-phenylbutyl]-2-[(4-pyridin-2-ylphenyl)methyl]hydrazinyl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate
UNII (FDA)	QZU4H47A3S

Computed Descriptors

Molecular Weight	704.9
XLogP3	5.6
Hydrogen Bond Donor Count	5
Hydrogen Bond Acceptor Count	9
Rotatable Bond Count	18
Exact Mass	704.38974802
Monoisotopic Mass	704.38974802
Topological Polar Surface Area	171
Heavy Atom Count	51
Formal Charge	0

Physical & Chemical Properties

Solubility	3.27e-03 g/L
LogP	4.5

Physical description & handling notes

• Solid
• Free base slightly soluble (4-5 mg/mL)
• White to pale yellow crystalline powder. Slightly soluble in water 4-5 mg/mL. pH of saturated solution 1.9 at 24 °C. /Sulfate salt/
• Oral: Capsules: 100 mg (of atazanavir) Reyataz, (Bristol-Myers Squibb), 150 mg (of atazanavir) Reyataz, (Bristol-Myers Squibb), 200 mg (of atazanavir) Reyataz, (Bristol-Myers Squibb).

GHS Hazard Classification

Reported hazard statements	H318 (66.7%), H319 (33.3%), H372 (66.7%), H411 (66.7%)

Documented Uses

• Human immunodeficiency virus (HIV) infection (treatment). Atazanavir sulfate is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. /Atazanavir Sulfate/
• Use (kg; approx.) in Germany (2009): >500
• Consumption (g per capita; approx.) in Germany (2009): 0.00611
• Atazanavir is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older weighing at least 5kg. Atazanavir is also indicated in combination with [cobicistat] and other antiretrovirals for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35kg.
• Atazanavir is an antiretroviral protease inhibitor that is used in the therapy and prevention of human immunodeficiency virus (HIV-1) infection and the acquired immunodeficiency syndrome (AIDS). Atazanavir can cause transient and usually asymptomatic elevations in serum aminotransferase levels, mild elevations in indirect bilirubin concentration and, rarely, clinically apparent, acute liver injury. In HBV or HCV coinfected patients, highly active antiretroviral therapy with atazanavir may result of an exacerbation
• Breast Feeding; Lactation; Milk, Human; Anti-Infective Agents; Antiviral Agents; Anti-HIV Agents; Anti-Retroviral Agents; HIV Protease Inhibitors

Synonyms

Atazanavir; 198904-31-3; Latazanavir; Zrivada; BMS-232632; atazanavirum; DTXSID9048691; QZU4H47A3S; CHEBI:37924; DTXCID5028617; RefChem:54330; J05AE08; CGP 73547; CGP-73547; BMS 232632; Atazanavir Base

Frequently Asked Questions

What are the CAS number and molecular formula of Atazanavir?

CAS 198904-31-3; molecular formula C38H52N6O7; molecular weight — g/mol.

What other names is Atazanavir known by?

Atazanavir, 198904-31-3, Latazanavir, Zrivada, BMS-232632, atazanavirum.

Is Atazanavir classified as hazardous?

Hazard statements reported: H318, H319, H372, H411.

What are the key physical properties of Atazanavir?

Solubility: 3.27e-03 g/L; LogP: 4.5.

Facts on this page are taken from PubChem (US National Library of Medicine) and Wikidata. Grade-specific data — assay, moisture, particle size, packaging, shelf life — is issued per batch on the COA and is not published here.